Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

RTTNews | 905 gün önce
Charles River Labs Boosts FY23 Outlook As Q2 Results Top Estimates

(RTTNews) - While reporting financial results for the first quarter on Thursday, Charles River Laboratories International, Inc. (CRL) raised its adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2023, to reflect the strong first-quarter financial performance and expectations for the remainder of the year that are largely consistent with its initial outlook.

For fiscal 2023, the company now projects earnings in the range of $7.45 to $8.45 per share and adjusted earnings in the range of $9.90 to $10.90 per share on revenues growth of 2.0 to 4.5 percent, with organic revenues growth of 5.0 to 7.5 percent.

Previously, the company expected earnings in the range of $7.40 to $8.60 per share and adjusted earnings in the range of $9.70 to $10.90 per share on revenues growth of 1.5 to 4.5 percent, with organic revenues growth of 4.5 to 7.5 percent.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $10.24 per share on revenue growth of 2.80 percent to $4.09 billion for the year. Analysts' estimates typically exclude special items.

For the first quarter, the company reported the net income attributable to common shareholders of $103.13 million or $2.01 per share, higher than $93.02 million or $1.81 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter was $2.78 per share, compared to $2.75 per share in the year-ago quarter.

Total revenue for the quarter increased 12.6 percent to $1.03 billion from $913.93 million in the same quarter last year. Organic revenue growth was 15.4 percent.

The Street was looking for earnings of $2.59 per share on revenues of $986.35 million for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Etiketler: CRL
read more
Charles River Laboratories Slashes FY24 Outlook - Update

Charles River Laboratories Slashes FY24 Outlook - Update

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2024.
RTTNews | 451 gün önce
Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

Charles River Labs Slashes FY22 Outlook; Q2 Adj. EPS Tops Estimates, Revenues Miss

While reporting financial results for the second quarter on Wednesday, Charles River Laboratories International, Inc. (CRL) slashed its earnings, adjusted earnings, revenue growth and organic revenue growth guidance for the full-year 2022, due primarily to headwinds associated with the CDMO business, foreign exchange, and interest expense due to the rising interest rate environment.
RTTNews | 1186 gün önce
Swiss Market Settles Moderately Lower

Swiss Market Settles Moderately Lower

The Switzerland market ended weak on Friday, in line with markets across Europe, as investors chose to trim down positions at several counters, continuing to react to earnings updates and assessing the developments on the trade front.
RTTNews | 16s 10 dakika önce
European Markets Close Weak After Cautious Session

European Markets Close Weak After Cautious Session

European markets closed weak on Friday, as investors reacted to a slew of earnings updates, regional economic data, and continued to assess the recent policy announcements from major central banks, and the developments on the trade front.
RTTNews | 16s 34 dakika önce